npj Breast Cancer (Mar 2023)

TGFβ-mediated MMP13 secretion drives myoepithelial cell dependent breast cancer progression

  • Shayin V. Gibson,
  • Elena Tomas Bort,
  • Lucía Rodríguez-Fernández,
  • Michael D. Allen,
  • Jennifer J. Gomm,
  • Iain Goulding,
  • Ulrich auf dem Keller,
  • Andrea Agnoletto,
  • Cathrin Brisken,
  • Barrie Peck,
  • Angus J. Cameron,
  • John F. Marshall,
  • J. Louise Jones,
  • Edward P. Carter,
  • Richard P. Grose

DOI
https://doi.org/10.1038/s41523-023-00513-6
Journal volume & issue
Vol. 9, no. 1
pp. 1 – 15

Abstract

Read online

Abstract Ductal carcinoma in situ (DCIS) is a non-obligate precursor of invasive breast cancer. Virtually all women with DCIS are treated, despite evidence suggesting up to half would remain with stable, non-threatening, disease. Overtreatment thus presents a pressing issue in DCIS management. To understand the role of the normally tumour suppressive myoepithelial cell in disease progression we present a 3D in vitro model incorporating both luminal and myoepithelial cells in physiomimetic conditions. We demonstrate that DCIS-associated myoepithelial cells promote striking myoepithelial-led invasion of luminal cells, mediated by the collagenase MMP13 through a non-canonical TGFβ – EP300 pathway. In vivo, MMP13 expression is associated with stromal invasion in a murine model of DCIS progression and is elevated in myoepithelial cells of clinical high-grade DCIS cases. Our data identify a key role for myoepithelial-derived MMP13 in facilitating DCIS progression and point the way towards a robust marker for risk stratification in DCIS patients.